Can I add Vascepa (icosapent ethyl) to a CKD stage 4 patient already on a maximally tolerated statin with triglycerides ≥150 mg/dL and atherosclerotic cardiovascular disease or diabetes?

Adding Vascepa (Icosapent Ethyl) to CKD Stage 4 Patients on Maximally Tolerated Statins

Yes, you can and should add Vascepa (icosapent ethyl) 4 grams daily to this CKD stage 4 patient, as the FDA-approved indication specifically includes patients with elevated triglycerides ≥150 mg/dL on maximally tolerated statin therapy who have either established ASCVD or diabetes with additional risk factors, and the REDUCE-IT trial demonstrated consistent cardiovascular benefit across all kidney function categories, including patients with eGFR <60 mL/min/1.73 m². 1, 2

FDA-Approved Indication Directly Supports This Use

• Vascepa is FDA-approved as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels (≥150 mg/dL) and established cardiovascular disease OR diabetes mellitus with 2 or more additional risk factors for cardiovascular disease. 1

• The standard dose is 2 grams twice daily (4 grams total per day) taken with food, and capsules must be swallowed whole without breaking, crushing, dissolving, or chewing. 1

Strong Evidence in CKD Populations

• In the REDUCE-IT RENAL subanalysis, patients with eGFR <60 mL/min/1.73 m² (which includes CKD stage 3 and worse) treated with icosapent ethyl had the largest absolute risk reduction for the primary composite endpoint (21.8% vs 28.9% with placebo; HR 0.71,95% CI 0.59-0.85; P=0.0002) and key secondary endpoint (16.8% vs 22.5%; HR 0.71,95% CI 0.57-0.88; P=0.001). 2

• The cardiovascular death reduction was numerically greatest in the eGFR <60 mL/min/1.73 m² group (7.6% vs 10.6% with placebo; HR 0.70,95% CI 0.51-0.95; P=0.02). 2

• Icosapent ethyl did not significantly alter eGFR or serum creatinine in CKD patients, indicating renal safety. 2, 3

• The relative risk reduction remained consistent across all baseline eGFR categories, with no significant interaction between kidney function and treatment effect. 2

Magnitude of Cardiovascular Benefit

• In the overall REDUCE-IT trial, icosapent ethyl reduced the primary composite endpoint by 25% (HR 0.75,95% CI 0.68-0.83; P<0.001), representing an absolute risk reduction of 4.8% and a number needed to treat of approximately 21 over 4.9 years. 4, 5

• Total ischemic events (first and subsequent) were reduced by 30% (61 vs 89 events per 1,000 patient-years; rate ratio 0.70,95% CI 0.62-0.78; P<0.0001). 5

• The benefit extended across all components of the primary endpoint, including cardiovascular death, myocardial infarction, stroke, coronary revascularization, and unstable angina. 5, 6

Safety Considerations in CKD Stage 4

Atrial Fibrillation Risk

• Patients with eGFR <60 mL/min/1.73 m² had numerically higher rates of atrial fibrillation/flutter (4.2% vs 3.0% with placebo; HR 1.42,95% CI 0.86-2.32; P=0.17), though this was not statistically significant. 2
• The risk of atrial fibrillation requiring hospitalization was increased overall in REDUCE-IT, with greater incidence in patients with previous history of atrial fibrillation or flutter. 1
• Clinical action: Screen for history of atrial fibrillation before initiating therapy and monitor for new-onset palpitations or irregular heart rhythm. 1

Bleeding Risk

• Patients with eGFR <60 mL/min/1.73 m² had numerically higher rates of serious bleeding (5.4% vs 3.6% with placebo; HR 1.40,95% CI 0.90-2.18; P=0.13), though not statistically significant. 2
• The hazard ratios for bleeding were similar across all eGFR categories (P-interaction=0.76), indicating no specific increased risk in advanced CKD. 2
• Bleeding risk is particularly elevated when combined with anticoagulants (warfarin) or antiplatelet agents (aspirin, clopidogrel). 1
• Clinical action: Monitor patients receiving concomitant antithrombotic medications for bleeding, but do not withhold Vascepa solely due to antiplatelet therapy, as most REDUCE-IT patients were on aspirin. 1, 2

Fish Allergy Considerations

• Vascepa contains ethyl esters of EPA obtained from fish oil, and patients with known hypersensitivity to fish or shellfish should be informed about potential allergic reactions. 1
• Clinical action: Advise patients to discontinue Vascepa and seek medical attention if allergic reactions occur. 1

Positioning Within Guideline-Based Therapy

• The 2018 ACC/AHA cholesterol guideline identifies CKD (eGFR <60 mL/min/1.73 m²) as a risk-enhancing factor that favors initiation of statin therapy in intermediate-risk patients. 4

• For patients with clinical ASCVD on maximally tolerated statin therapy with LDL-C ≥70 mg/dL, the guideline recommends adding ezetimibe (Class IIa) before considering PCSK9 inhibitors. 4, 7

• Vascepa occupies a distinct therapeutic niche: It addresses residual cardiovascular risk driven by elevated triglycerides and inflammation, independent of LDL-C lowering, making it complementary rather than competitive with ezetimibe or PCSK9 inhibitors. 4, 8, 6

• The expanded FDA indication allows co-administration of Vascepa for elevated triglycerides with statin treatment, enabling effective residual risk reduction beyond what can be achieved with intensive LDL-C control alone. 8

Common Pitfalls to Avoid

• Do not confuse Vascepa with combination omega-3 products: Omega-3 fatty acid preparations containing both EPA and docosahexaenoic acid (DHA) are NOT indicated for cardiovascular risk reduction and should be actively deprescribed. 6

• Do not delay Vascepa while optimizing LDL-C: Unlike the sequential approach for ezetimibe and PCSK9 inhibitors, Vascepa can be initiated simultaneously with statin optimization because it targets a different residual risk pathway (triglycerides and inflammation rather than LDL-C). 4, 8

• Do not withhold due to CKD stage 4: The evidence specifically supports use in advanced CKD, with the greatest absolute benefit observed in patients with eGFR <60 mL/min/1.73 m². 2

• Do not use Vascepa as monotherapy: It is FDA-approved only as an adjunct to maximally tolerated statin therapy, not as a replacement. 1

Contraindications

• Known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components is the only absolute contraindication. 1